Future of Pharmacogenetics in Cardiovascular Diseases
作者： Rianne van Schie , Talitha Verhoef , Anke-Hilse Maitland-Van Der Zee , Anton de Boer , Felix van der Meer
DOI: 10.5772/27500
关键词: Intensive care medicine 、 Increased risk 、 Pharmacogenetics 、 Pharmacology 、 Medicine 、 Pharmacotherapy 、 Drug response 、 Drug reaction
摘要: Introduction: Pharmacogenetics is the study of variations in DNA sequence as related to drug response (European Medicines Agency [EMA], 2007). Several gene-drug interactions have been discovered field cardiovascular diseases (CVDs). These can help identify nonresponse drugs, estimate dose requirements or an increased risk developing adverse reactions. An individualized approach based on pharmacogenetic testing will provide physicians and pharmacists with tools for decision making about pharmacotherapy. While pharmacogenetic already part everyday practice oncology, it not widely implemented CVDs. However, the near future, pharmacogenetics probably also play a valuable role this well.
core.ac.uk
intechopen.com
narcis.nl参考文章(48)
Jean-Philippe Collet, Stephen O’Connor, Clinical effects and outcomes with new P2Y12 inhibitors in ACS. Fundamental & Clinical Pharmacology. ,vol. 26, pp. 16- 18 ,(2012) , 10.1111/J.1472-8206.2011.00984.X
Silvia Maria Custódio das Dôres, Sarah L. Booth, Ligia Aújo Martini, Victor Hugo de Carvalho Gouvêa, Carlos Roberto Padovani, Francisco Humberto de Abreu Maffei, Álvaro Oscar Campana, Sérgio Alberto Rupp de Paiva, Relationship between diet and anticoagulant response to warfarin: a factor analysis. European Journal of Nutrition. ,vol. 46, pp. 147- 154 ,(2007) , 10.1007/S00394-007-0645-Z
SLCO1B1 variants and statin-induced myopathy--a genomewide study The New England Journal of Medicine. ,vol. 359, pp. 789- 799 ,(2008) , 10.1056/NEJMOA0801936
Joseph A. Jakubowski, Jeffrey S. Riesmeyer, Sandra L. Close, Amy G. Leishman, David Erlinge, TRITON and Beyond: New Insights into the Profile of Prasugrel. Cardiovascular Therapeutics. ,vol. 30, pp. 174- 182 ,(2012) , 10.1111/J.1755-5922.2011.00263.X
Ankie Harmsze, Jochem W. van Werkum, Heleen J. Bouman, Henk J. Ruven, Nicolien J. Breet, Jurrien M. Ten Berg, Christian M. Hackeng, Mathieu M. Tjoeng, Olaf H. Klungel, Anthonius de Boer, Vera H. Deneer, Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation. Pharmacogenetics and Genomics. ,vol. 20, pp. 18- 25 ,(2010) , 10.1097/FPC.0B013E328333DAFE
Simone Rost, Andreas Fregin, Vytautas Ivaskevicius, Ernst Conzelmann, Konstanze Hörtnagel, Hans-Joachim Pelz, Knut Lappegard, Erhard Seifried, Inge Scharrer, Edward G. D. Tuddenham, Clemens R. Müller, Tim M. Strom, Johannes Oldenburg, Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 Nature. ,vol. 427, pp. 537- 541 ,(2004) , 10.1038/NATURE02214
A. M. Harmsze, J. W. van Werkum, J. M. ten Berg, B. Zwart, H. J. Bouman, N. J. Breet, A. W. J. van 't Hof, H. J. T. Ruven, C. M. Hackeng, O. H. Klungel, A. de Boer, V. H. M. Deneer, CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case–control study European Heart Journal. ,vol. 31, pp. 3046- 3053 ,(2010) , 10.1093/EURHEARTJ/EHQ321
T SCHALEKAMP, M OOSTERHOF, E VANMEEGEN, F VANDERMEER, J CONEMANS, M HERMANS, I MEIJERMAN, A DEBOER, Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status. Clinical Pharmacology & Therapeutics. ,vol. 76, pp. 409- 417 ,(2004) , 10.1016/J.CLPT.2004.08.006
Talitha I Verhoef, William K Redekop, Josep Darba, Mary Geitona, Dyfrig A Hughes, Uwe Siebert, Anthonius de Boer, Anke-Hilse Maitland-van der Zee, Rita Barallon, Montserrat Briz, Ann Daly, Elisabeth Haschke-Becher, Farhad Kamali, Julia Kirchheiner, Vangelis G Manolopoulos, Munir Pirmohamed, Frits R Rosendaal, Rianne MF van Schie, Mia Wadelius, None, A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives Pharmacogenomics. ,vol. 11, pp. 989- 1002 ,(2010) , 10.2217/PGS.10.74
Mark Sculpher, Karl Claxton, Establishing the Cost‐Effectiveness of New Pharmaceuticals under Conditions of Uncertainty—When Is There Sufficient Evidence? Value in Health. ,vol. 8, pp. 433- 446 ,(2005) , 10.1111/J.1524-4733.2005.00033.X